Diagnosing congenital Cytomegalovirus infection: Don&apos;t get rid of dried blood spots by L. Pellegrinelli et al.
DEBATE Open Access
Diagnosing congenital Cytomegalovirus
infection: don’t get rid of dried blood spots
Laura Pellegrinelli1* , Luisella Alberti2, Elena Pariani1, Maria Barbi1 and Sandro Binda1
Abstract
Background: Congenital Cytomegalovirus (cCMV) is a serious global public health issue that can cause irreversible
fetal and neonatal congenital defects in symptomatic or asymptomatic newborns at birth. In absence of universal
cCMV screening, the retrospective diagnosis of cCMV infection in children is only possible by examining Dried
Blood Spot (DBS) samples routinely collected at birth and stored for different time spans depending on the
newborn screening regulations in force in different countries. In this article, we summarize the arguments in favor
of long-term DBS sample storage for detecting cCMV infection.
Main text: CMV infection is the most common cause of congenital infection resulting in severe defects and
anomalies that can be apparent at birth or develop in early childhood. Sensorineural hearing loss is the most
frequent consequence of cCMV infection and may have a late onset and progress in the first years of life. The
virological diagnosis of cCMV is essential for clinical research and public health practices. In fact, in order to assess
the natural history of CMV infection and distinguish between congenital or acquired infection, children should be
diagnosed early by analyzing biological samples collected in the first weeks of life (3 weeks by using viral culture
and 2 weeks by molecular assays), which, unfortunately, are not always available for asymptomatic or mildly
symptomatic children. It now seems possible to overcome this problem since the CMV-DNA present in the blood
of congenitally infected newborns can be easily retrieved from the DBS samples on the Guthrie cards routinely
collected and stored within 3 days from birth in the neonatal screening program for genetic and congenital
diseases. Early collection and long-term storage are inexpensive methods for long-term bio-banking and are the key
points of DBS testing for the detection of cCMV.
Conclusion: DBS sampling is a reliable and inexpensive method for long-term bio-banking, which enables to
diagnose known infectious diseases - including cCMV - as well as diseases not jet recognized, therefore their
storage sites and long-term storage conditions and durations should be the subject of political decision-making.
Background
Dried blood spot (DBS) sampling was first introduced in
the early 1960s by Dr. Robert Guthrie who used few mi-
croliters of blood obtained by pricking the heel or finger
and then blotted and dried onto filter paper in order to de-
tect phenylketonuria in newborns [1]. DBS is a simple way
of collecting, storing and transporting biological samples,
since it is a non-invasive and inexpensive sampling method
that requires a smaller amount of blood than other new-
born screening tests [2].
The most important application of DBS testing is the
retrospective diagnosis of congenital Cytomegalovirus
(cCMV) infection; since CMV is the most common
cause of sensorineural hearing loss (SNHL), CMV diag-
nosis should be recommended when children fail new-
born hearing screening and should be carried out within
the first weeks of life [3]. Although cCMV infection is
the most common congenital infection, few people are
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aware of this infection and how to control or prevent it
[4]. However, although DBS is a promising method for
collecting microliters of blood samples, there are still
some limitations. Research has demonstrated the effect-
iveness of the DBS method for the collection and long-
term storage of blood samples and it is known to be an
inexpensive method for long-term bio-banking and a
useful diagnostic tool for cCMV diagnosis. In this article,
we summarize the arguments in favour of long-term
storage and using the DBS method in diagnosis of
cCMV infection.
Main text
cCMV infection is a serious global health issue affecting
0.2–2.2% of newborns in all populations [3]. It causes per-
manent damage in 5–40% of infected children - either
symptomatic or not at birth - with SNHL being the most
frequent (14%), serious and permanent impairment [3, 5–7].
The virological diagnosis of cCMV infection by detect-
ing either the virus or its components is essential for
clinical, research and public health purposes. cCMV in-
fection is often insidious as it is most often asymptom-
atic or poorly symptomatic at birth while it can result in
defects that appear during infancy from birth up until
six years of age, in at least 13.5% of congenitally infected
children [7], a percentage which is probably underesti-
mated. Besides the lack of clinical suspicion at birth,
diagnosis of the infection may be hampered due to its very
strict diagnostic timing [8]. In fact, after 2-3 weeks of life
CMV detection may be due to a congenital infection or
postnatal breast milk- or transfusion-acquired infections.
Consequently, in order to evaluate the natural history of
cCMV infection, the relationship between cCMV infection
and the presence of defects at birth or their emergence
during childhood, it is essential to test biological samples
collected in the first 15-21 days of life using nucleic acids
test (NAT) assays and PCR technology [8].
A solution to these issues was offered by the fact that
CMV-DNA present in the blood of congenitally infected
newborns can be easily identified in DBS samples, ob-
tained from heel or finger pricks and spotted onto filter
paper (Guthrie cards), which are routinely collected
within 3 days from birth in most countries under the
neonatal screening for genetic and congenital diseases
framework [9].
The standard DBS collection methods, transfer of
blood onto the paper and the storage and transportation
of DBS samples have been described in detail [10]. In
brief, DBS specimens are usually collected from new-
borns by pricking the heel or big toe with a single-use
safety lancet, and the drops of blood are spotted onto
pre-printed circles on specially manufactured DBS
paper, without touching the circle area and ideally one
drop per circle. The pre-printed circles have to be
homogenously filled on both sides of the card. After col-
lection, the DBS samples should dry in an open space at
room temperature (15–22 °C) for a minimum of 2–3 h
before storage or transportation. After drying, DBS sam-
ples can be stored at room temperature for many years.
The universality of early collection and long-term stor-
age at regional screening centres represent an inexpen-
sive method for long-term bio-banking [11, 12] and are
the key points of DBS testing for the detection of cCMV.
Besides the research aspect, the ascertainment of specific
health impairments is of great importance both for the
clinician managing the congenitally impaired child and
for parents seeking a clear-cut diagnosis.
Prospective and retrospective studies have demonstrated
that the detection of CMV via DBS sample testing by viral
DNA extraction and amplification using PCR methods
proved to be as sensitive (64–100%) and specific (99–
100%) in diagnosing the congenital infection as the gold
standard technique of saliva or urine PCR-testing [8].
However, the DBS test sensitivity change from study to
study, resulting in a wide range of values; the best sum-
mary of the evidence has been provided by a recent meta-
analysis of 15 studies (including 26,007 neonates) that
evaluated the performance of DBS-PCR tests, showing an
overall sensitivity and specificity of 84.4% (95% CI; 81.2–
87.2%) and 99.9% (95% CI; 99.8–99.9%), respectively [13].
This meta-analysis, considering both prospective screen-
ing studies (including asymptomatic children) and retro-
spective studies (involving symptomatic children only),
has revealed that the sensitivity of DBS testing was signifi-
cant lower in screening studies than in retrospective stud-
ies (62.3% vs 94.5%), thus concluding that DBS-PCR assay
for CMV detection is more suitable for retrospective diag-
nosis than for screening program [13].
Sensitivity to detect CMV in DBS samples compared to
saliva and urine is variable across studies mainly due to
the DNA extraction method including in-house protocol
and commercial kit [14–18] and considering the very lim-
ited sample volume available. Although some authors have
raised the issue of the fact that DBS offers lower analytical
sensitivity than saliva or urine testing [19–22], a recent
work has shown promising results on DNA extraction
optimization by maximizing the quality and yield of DNA
from DBS and developing rapid automated methods for
the detection of CMV-DNA [16]. Koontz et al. has re-
cently demonstrated that rapid and cost-effective DNA
extraction methods such as thermal shock and “KOH-Tris
and DNA Extract All” can sensitively detect CMV from
DBS as accurately as silica-column and bead-based extrac-
tion methods (Table 1). Moreover, Berg et al. have devel-
oped efficient protocols for extraction and amplification of
DNA from DBS for CMV detection and genotyping by
combining different steps of sample lysis and extraction
[23]. However, it should be considered that, besides
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technical aspects that toughly affect the sensitivity of DBS
testing, there may be several biological issues; in fact, it is
well-known that: i) CMV viral load in blood is usually sig-
nificantly lower than in saliva and urine [24], ii) CMV viral
load is significantly lower in asymptomatic children than
in children with moderate/severe symptomatic disease
[25], and iii) viremia may not be present in all infants with
proven cCMV infection even by using PCR testing of
whole blood samples [25]. All these aspects make the true
sensitivity of DBS testing still uncertain, particularly in
consideration that a negative result to DBS test could not
rule out categorically a cCMV infection.
In order to prevent the onset or the progression of
SNHL and other CMV-associated disabilities in both
asymptomatic and symptomatic newborns and to evalu-
ate the role of cCMV in children with severe neuro-
logical sequelae, it is essential to carry out a universal or
targeted CMV screening in the framework of the neo-
natal hearing screening (NHS) program. In this scenario,
in the past decade, an ever-increasing number of studies
has demonstrated that urine and saliva (collected within
3 weeks from birth if CMV is diagnosed by using viral
culture and within 2 weeks if CMV is identified via mo-
lecular assays [26]) are specimens endowed with high
sensitivity and easily manageable to be used in both uni-
versal and targeted screening programs [21, 27–30]. In
general, CMV screening programs are based on viral de-
tection in saliva swabs within 2–3 weeks of life [21, 27–
30]; if the saliva sample is positive for CMV, a urine
sample is also collected within 2–3 weeks of birth: the
diagnosis of cCMV infection is based on a positive urine
test [21, 27–30]. However, there is a concern that some
logistic problems can delay the timing of urine sample
collection, and thus the diagnosis of cCMV infection; in
these cases, it can be addressed by analyzing DBS sam-
ples universally collected at birth [11].
Moreover, the sensitivity of DBS for the retrospective
diagnosis of cCMV has been clearly proved in children
developing the related-illness in the first few years of life
[31, 32] and it is acknowledged that many serious health
Table 1 Qualitative assessment of DBS testing; type of extraction, PCR protocol, DBS samples input and overall percentage of DBS
punches that tested positive for CMV DNA
DNA Extraction method PCR protocol DBS
samples
imput
% of CMV-positive DBS with low
viral load (< 4 log10 copie/ml)
% of CMV-positive DBS with moderate-
high viral load (> 4 log10 copie/ml)
References
QIAamp DNA Investigator
Kit (QIAGEN)
Real-time PCR 3 punches
of 3.2 mm
88% 97% [15]
QIAamp DNA Investigator
Kit on QIAcube (QIAGEN)
Real-time PCR 3 punches
of 3.2 mm
79% 100%
QIAamp DNA Mini Kit
(QIAGEN)
Real-time PCR 3 punches
of 3.2 mm
46% 91%
Thermal shock (methods by
Barbi et al.)
Real-time PCR 1 punches
of 6 mm
100% 100%
Thermal shock (methods by
Barbi et al.)
Real-time PCR 3 punches
of 3.2 mm
60% 90% [16]
KOH-Tris Extracta DBS
(QuantaBio)
Real-time PCR 3 punches
of 3.2 mm
80% 98%
DNA Extract All (Applied
Biosystems)
Real-time PCR 3 punches
of 3.2 mm
83% 98%
Gentra Puregene (QIAGEN) Real-time PCR 3 punches
of 3.2 mm
67% 100%
M48 MagAttract DNA Mini
ki (QIAGEN)
Real-time PCR 3 punches
of 3.2 mm
58% 85%
Manual phenol-chloroform
method
Conventional
PCR
1 whole
Spot (Ø 1
cm)
66%* [18]
Manual phenol-chloroform
method
Real-time PCR 1 whole
Spot
(Ø1cm)
82%*
easyMAG (BioMérieux) Conventional
PCR
1 whole
Spot (Ø 1
cm)
45%*
easyMAG (BioMerieux) Real-time PCR 1 whole
Spot (Ø 1
cm)
73%*
* Viral load not provided
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conditions - such as SNHL, vestibular disorders, abnor-
malities of cortical development, pachygyria, cholestasis
[31–34] and autism spectrum disorder [35] - have bene-
fited from a retrospective DBS analysis. The opportunity
to carry out retrospective studies to find a causal relation-
ship between congenital infections and pathological condi-
tions of unknown or debated origin suffers from the
length of storage time of residual DBS specimens. In our
experience, the collection of residual DBS samples to de-
termine the role of cCMV in cases of SNHL (identified by
failed neonatal hearing screenings or diagnosed clinically
in childhood) occurred in two-thirds of the cases under
study (unpublished data). The fact that the cards are dis-
posed of after a fixed, and sometimes short, conservation
period is the main cause of this drawback (unpublished
data). The impossibility of diagnosing cCMV due to the
disposal of residual DBS specimens is frustrating.
DBS storage times and its purpose made of residual
newborn screening DBS specimens depends on the new-
born screening programs implemented in different coun-
tries, federal states or regions in the same country [11, 12].
Wang et al. have stated that the storage times of DBS sam-
ples vary from 14 days to 18 years among 10 countries
[13]. According to the Advisory Committee on Heritable
Disorders in Newborns and Children there are two dis-
tinct approaches regarding the storage of residual new-
born screening specimens: i) short-term storage (< 3
years), primarily for standard program use and ii) long-
term storage (> 18 years), for standard screenings and fur-
ther public health research [11]. There are also two dis-
tinct methodologies regarding the use of residual DBS: i)
the opt-in approach, required for explicit consent to sec-
ondary use of residual samples and ii) the opt-out ap-
proach that presumes consent for the secondary use of
residual biological samples unless explicitly refused [12].
The sensitivity of 12- to 18-year-old DBS specimens were
81.2%, and the duration of DBS storage did not affect the
detection of CMV-DNA [36].
The choice of short-term storage (< 3 years) of DBS in
screening centres may be due to the fact that several social
and ethical issues have arisen over the potential uses of re-
sidual specimens and patient privacy. However, short-
term storage can hinder the cCMV diagnosis after the first
few years of life, thus making the diagnosis of CMV-
related sequelae an unaddressed issue. The main issue is
to find a balance between the need for privacy and the
possible public health research uses and benefits. The
right DBS long-term storage might be to raise public
awareness and parental knowledge on the usefulness of
DBS samples (like the cCMV issue), through patient edu-
cation and counselling and educational programs. In this
way, parents might be asked to donate the residual speci-
mens and parents can request that a part of the donated
sample is stored for future use. Moreover, collecting
paired DBS specimens and giving one to the child’s par-
ents could solve the DBS sample storage issue.
Conclusions
Concluding, we state that DBS long-life storage is essen-
tial! Since DBS samples can be a helpful and inexpensive
diagnostic tools for long-term bio-banking that enable
diagnosis of leading infectious diseases - including cCMV-
as well as further disease not jet recognized. Long-term
DBS storage and usage should be subject to political
decision-making.
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